A Phase I Trial of Oral Ridaforolimus (AP23573; MK-8669) in Combination with Bevacizumab for Patients with Advanced Cancers

Oral ridaforolimus (40 mg QDx5/wk) is feasible to combine with standard doses of bevacizumab, although careful patient selection would be needed to mitigate the risk of bowel perforation-related adverse events. Combination therapy produced prolonged stable disease in several heavily pretreated patients.